Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT₃ receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States

By Schwartzberg Lee   Morrow Gary   Balu Sanjeev   Craver Chris   Gayle Julie   Cox David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1613-1622

Informa Healthcare

Access to resources Recommend Favorite

QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist

By  

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 3, 2015-05 ,pp. : 436-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy-Induced Emesis in Elderly Cancer Patients: The Role of 5-HT₃-Receptor Antagonists in the First 24 Hours

By  

Gerontology, Vol. 51, Iss. 5, 2005-08 ,pp. : 287-296

Karger

Access to resources Recommend Favorite

Haloperidol Versus 5‐HT₃ Receptor Antagonists for Postoperative Vomiting and QTc Prolongation: A Noninferiority Meta‐Analysis and Trial Sequential Analysis of Randomized Controlled Trials

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 58, Iss. 2, 2018-02 ,pp. : 131-143

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hypnosis in the Treatment of Anticipatory Nausea and Vomiting in Patients Receiving Cancer Chemotherapy

By  

Oncology, Vol. 59, Iss. 2, 2000-08 ,pp. : 100-104

Karger

Access to resources Recommend Favorite